Chemotherapy Effect Clinical Trial
Official title:
The Effect of Peppermint Oil on Nausea, Vomiting and Retching in Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial
The aim of this study was to determine the effect of peppermint oil upon incidence of nausea, vomiting and retching, nause severity, and the usage amount of antiemetics in cancer patients undergoing chemotherapy.
Nausea, vomiting and retching symptoms are among the most common adverse effects of
chemotherapy and are defined with expressions like "the biggest problem including pain" by
patients. Chemotherapy-induced nausea and vomiting (CINV)' is reported leads to
fluid-electrolyte imbalance, dehydration, loss of weight, physiological effects caused by
poor drug absorption or decreased elimination from kidneys as well as negative effects in
one's social life, work-life, activities of daily life and psychological status. Also,
nausea-vomiting may cause some patients to refuse chemotherapy or to discontinue the
treatment. Inadequate control of CINV leads patients to integrative health practices.
The study was realized as a randomized controlled study in order to explore the effect of use
of 3% peppermint oil applied on lips three times a day during the five days following
chemotherapy upon incidence nausea, vomiting, and retching, nausea severity and quantity use
of antiemetics in cancer patients undergoing chemotherapy.The study was initiated on the
10.09.2017 and in this study were interviewed with 250 patients. 90 patients that met
inclusion criteria were contacted. The study was completed with 36 intervention patients and
with 44 control patients (See Fig. 1). For determine to sample size, while patients were
being allocated to the study groups, post hoc power analysis was periodically done with the
data obtained. The sample size for this study was calculated using the MedCalc (32-bit). The
process continued until the necessary sample size was reached. According to power analysis, α
= 0.05 and β =0.20, and the power of the study was 99.9%.
Randomization In order to provide randomization was preferred ballot method. As a result of
the ballot, the first patient who inclusion criteria of study was allocated to the
intervention group while the next one to the control group. After participant enrollment,
patients were assigned to the two groups in a 1:1 ratio according to this rule. Because of it
is not known whether nausea/vomiting experience of patients who first time chemotherapy
receiving, study groups included patients receiving two or more chemotherapy.
Interventions 2.4.1. The control group The control group underwent only the routine
treatment. The patients in the control group, Patient Watch Chart, Patient Nausea Severity
Follow-up Form, and INVR, marked by patients and They were returned the duly completed these
forms to the researcher when they came to hospital for the next chemotherapy treatment.
Patient Watch Chart, and INVR skala of patients who illiterate were filled in by the
pollster, according to expression of patient. In order to fill in Patient Watch Chart, and
INVR phone interviews were made twice a day (morning-evening) by the pollster and the
participants at a suitable time determined together.
2.4.2. Intervention group The patients in the intervention group received routine medical
treatment program and were asked to put one drop of peppermint oil upon lips following
chemotherapy administration. Before peppermint oil application; the researcher theoretically
and practically provided a training of 8-10 minutes about the use of peppermint oil and the
patients were requested to apply this oil three times a day according to "Oil Practice Guide"
(See Fig. 2) in the morning (09:00), at noon (15:00) and in the evening (21:00). The mobile
phones of the participants were set to these hours and the alarm system continued in this
manner for five days. The participants whose mobile phones were not set to these hours were
called by the researcher in order to recall them of the protocol. Before peppermint oil
application, Patient Opinion Form (pre-application) were asked to the participants and their
answers were written down. Similarly; after peppermint oil application, same form
(post-application) were asked and the answers were written down. Patient Watch Chart, Patient
Nausea Severity Follow-up Form, and INVR, marked by patients and They were returned the duly
completed these forms to the researcher when they came to hospital for the next chemotherapy
treatment. Patient Watch Chart, and INVR skala of patients who illiterate were filled in by
the pollster, according to expression of patient. In order to fill in Patient Watch Chart,
and INVR phone interviews were made twice a day (morning-evening) by the pollster and the
participants at a suitable time determined together.
Patients in the intervention and control groups were allowed to take standard antiemetic
medications and other drugs taken for different medical problems during and after the day of
peppermint oil application. As a part of standard antiemetic treatment; patients were given "
in isotonic solution 5-HT3 receptor antagonists (palonosetron, granisetron (Kytril))+
steroids (dexamethazon (Decort)) + antihistaminic (Avil or Systral ampul) + Metpamid ampul"
before chemotherapy.
Onzyd 8 mg (ondansetron) + metpamid tb. has been prescribed by oncologist, for able to use at
patient's home.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06376604 -
Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies
|
N/A | |
Completed |
NCT03753542 -
Effect of Nurse-led Education on Parent's Anxiety and Depression on Managing Side Effects of Chemotherapy
|
N/A | |
Not yet recruiting |
NCT05022628 -
Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis
|
Phase 4 | |
Completed |
NCT04207359 -
Effects of Creatine Supplementation in Breast Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04489173 -
TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer
|
Phase 2 | |
Completed |
NCT04173195 -
Comfort Talk (CT) During Outpatient Chemotherapy
|
N/A | |
Recruiting |
NCT06041477 -
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
|
Phase 3 | |
Recruiting |
NCT05014399 -
Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
|
||
Recruiting |
NCT03275194 -
HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy
|
Phase 2 | |
Recruiting |
NCT04808466 -
Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
|
Phase 2 | |
Recruiting |
NCT06421610 -
OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.
|
Phase 1 | |
Completed |
NCT05131490 -
Effect on Adaptation to Cancer of Mobile Application Developed for Gynecological Cancer Patients
|
N/A | |
Recruiting |
NCT06043999 -
Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients
|
N/A | |
Recruiting |
NCT05515796 -
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
|
Phase 2 | |
Not yet recruiting |
NCT04845490 -
Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
|
Phase 2 | |
Recruiting |
NCT04989985 -
S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT05992337 -
New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
|
||
Recruiting |
NCT05424692 -
Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer
|
N/A | |
Enrolling by invitation |
NCT04027478 -
Can Fasting Decrease the Side Effects of Chemotherapy?
|
N/A | |
Completed |
NCT04116138 -
Antisecretory Factor in Primary Glioblastoma 1
|
Phase 1/Phase 2 |